Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
2.800
-0.150 (-5.08%)
At close: Nov 20, 2024, 4:00 PM
2.820
+0.020 (0.71%)
Pre-market: Nov 21, 2024, 7:12 AM EST
Autolus Therapeutics Revenue
Autolus Therapeutics had revenue of $10.09M in the twelve months ending September 30, 2024, up 82.71% year-over-year. In the year 2023, Autolus Therapeutics had annual revenue of $1.70M, down -73.30%.
Revenue (ttm)
$10.09M
Revenue Growth
+82.71%
P/S Ratio
64.41
Revenue / Employee
$21,425
Employees
471
Market Cap
745.14M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.70M | -4.66M | -73.30% |
Dec 31, 2022 | 6.36M | 4.03M | 172.96% |
Dec 31, 2021 | 2.33M | 615.00K | 35.86% |
Dec 31, 2020 | 1.72M | -1.19M | -41.02% |
Dec 31, 2019 | 2.91M | 1.44M | 97.55% |
Dec 31, 2018 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 30, 2016 | Pro | Pro | Pro |
Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Healthcare Services Group | 1.70B |
Embecta | 1.12B |
Avanos Medical | 681.50M |
Castle Biosciences | 311.88M |
AbCellera Biologics | 32.96M |
Liquidia | 15.61M |
Relay Therapeutics | 10.01M |
AUTL News
- 8 hours ago - AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market - Seeking Alpha
- 8 days ago - Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) - GlobeNewsWire
- 23 days ago - Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - GlobeNewsWire
- 2 months ago - Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case - Seeking Alpha
- 3 months ago - Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 - GlobeNewsWire
- 5 months ago - Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress - GlobeNewsWire